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Abstract
Background: Iron deficiency anaemia is a common problem in pregnancy despite national recommendations and
guidelines for treatment. The aim of this study was to appraise the evidence against the UK National Screening
Committee (UKNSC) criteria as to whether a national screening programme could reduce the prevalence of iron
deficiency anaemia and/or iron deficiency in pregnancy and improve maternal and fetal outcomes.
Methods: Search strategies were developed for the Cochrane library, Medline and Embase to identify evidence
relevant to UK National Screening Committee (UKNSC) appraisal criteria which cover the natural history of iron
deficiency and iron deficiency anaemia, the tests for screening, clinical management and evidence of cost
effectiveness.
Results: Many studies evaluated haematological outcomes of anaemia, but few analysed clinical consequences.
Haemoglobin and ferritin appeared the most suitable screening tests, although future options may follow recent
advances in understanding iron homeostasis. The clinical consequences of iron deficiency without anaemia are
unknown. Oral and intravenous iron are effective in improving haemoglobin and iron parameters. There have been
no trials or economic evaluations of a national screening programme for iron deficiency anaemia in pregnancy.
Conclusions: Iron deficiency in pregnancy remains an important problem although effective tests and treatment
exist. A national screening programme could be of value for early detection and intervention. However, high quality
studies are required to confirm whether this would reduce maternal and infant morbidity and be cost effective.
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Background
Anaemia in pregnancy is a worldwide problem. The inci-
dence and aetiology vary considerably between low and
high-income countries, with iron deficiency considered
the most common cause in the latter. Somewhat surpris-
ingly, recent prevalence estimates of maternal anaemia
in pregnancy in the UK and other high-income coun-
tries, suggest there has been no significant decrease in
the prevalence of anaemia in pregnancy in the last
decade [1]. The UK prevalence of maternal anaemia in
the antenatal period was estimated as 24 % in a recent
cross sectional study [2].
There is a spectrum of iron deficiency in pregnancy
ranging from iron depletion without anaemia (absent
iron stores with a normal haemoglobin concentration)
to overt anaemia [3]. Although iron deficiency in preg-
nancy is, in principle, identifiable, treatable and possibly
preventable with iron supplementation, there is uncer-
tainty about its significance as a clinical and public
health problem, and whether systematic screening and
treatment for iron deficiency and iron deficiency an-
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The UK guidelines that underpin the clinical manage-
ment of iron deficiency anaemia in pregnancy are sum-
marised in Table 1. [4–6]. There are also a variety of
international and national guidelines. Guidance from the
World Health Organisation [7], United States of America
[8, 9], Australia and New Zealand [10] has been reviewed
elsewhere [11, 12]. Recommendations for current practice
in the UK are to assess the mother’s haemoglobin concen-
tration at booking and at 28 weeks’ gestation and ensure
there are systems in place to follow up abnormal results
[4]; routine assessment of iron status is not recommended
in all women [5].
Whilst ‘screening’ for iron deficiency anaemia in preg-
nancy is consistently recommended in these guidelines,
Table 1 Summary of existing guidance for the management of anaemia or iron deficiency anaemia (IDA) in pregnancy in the UK
Body Year Title Recommendations in the antenatal period (evidence level)
British Committee for Standards
in Haematology [5]
2012 UK guidelines on the
management of iron deficiency
in pregnancy
• Women with Hb <110 g/l or <105 g/l in the second and third trimesters,
should have a trial of oral iron as the first line diagnostic test for
microcytic or normocytic anaemia; an increased Hb after two
weeks of therapy is taken to be confirmatory (1B).
• Refer to secondary care for further investigation for other causes of
anaemia if Hb does not improve after 2 weeks, severe <70 g/l,
significant symptoms or late gestation (>34 weeks) (2B).
• Routine ferritin testing in non-anaemic pregnant women is not
recommended unless they are ‘at risk’ of iron deficiency (2B).
• Treatment is suggested where ferritin is <30 mcg/l with rapid review
and follow up of results (2A)
Women at risk include:
1. anaemic women where estimation of iron stores is necessary, e.g.
women with haemogloblinopathies or prior to parenteral iron
replacement
2. those who are not anaemic but at risk of iron depletion (previous
anaemia, multiparity > 3, consecutive pregnancy, vegetarians, teenage
pregnancies, recent history of bleeding)
3. Non-anaemic women where estimation of iron stores is necessary as
significant blood loss may occur (high bleeding risk, Jehovah
witnesses).
• Consider IV iron from the 2nd trimester onwards if absolute non-
compliance or intolerance to oral iron or proven malabsorption (1A)
• All women should receive dietary counselling detailing iron rich foods,
inhibitory factors reinforced by provision of an information leaflet (1A)
• Evidence level AHCPR methodology
National Institute for Health
and Care Excellence Clinical [4]
2008 Antenatal Care: routine care for
the healthy pregnant woman.
Guideline 62.
• Hb should be checked at booking and 28 weeks when other blood
screening tests are being carried out (B)
• nutritional information should be offered to all pregnant women (A)
• Hb <110 g/l 1st trimester and 105 g/l at 28 weeks should be
investigated and iron supplementation considered in indicated (A)
• iron supplementation should not be offered routinely as there are
unpleasant maternal side effects with no clearly demonstrated maternal
and infant benefits (A)
• Evidence level GRADE methodology
Royal College of Obstetricians
and Gynaecologists [6]
2007 Blood Transfusions in Obstetrics
Green-top 47
• Anaemia should be treated to reduce probability of transfusion
requirement (GPP).
• If Hb <105 g/l in the antenatal period, consider haematinic deficiency
(GPP).
• Once haemoglobinopathies have been excluded, oral iron should be the
first-line treatment for iron deficiency (GPP).
• Parenteral iron is indicated when oral iron is not tolerated, absorbed or
patient compliance is in doubt (GPP).
• Evidence level AHCPR methodology + GPP (clinical good practice point
where evidence lacking)
Abbreviations: (AHCPR) US Agency for Health Care and Policy Research, (GRADE) Grading of Recommendations Assessment, Development and Evaluation; GPP
clinical good practice point
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the approach in practice differs significantly by country.
Screening in this review refers to a systematic integrated
programme targeting all pregnant women; including test-
ing, diagnosis, treatment, training and quality assurance.
As yet, there has been no formal screening programme to
implement these recommendations in the UK.
The aim of this analysis was to review the case for screen-
ing pregnant women for iron deficiency and iron deficiency
anaemia, using, as a framework, the criteria set out by the
UK National Screening Committee [13]. Additional objec-
tives were to identify any gaps in the evidence and outline
opportunities for further research to answer the question
about the case for screening.
Methods
The UKNSC screening programme appraisal criteria
were accessed through the national UK screening portal
[13]. The UKNSC outline 22 criteria that must be met
before a systematic population screening programme for
a condition is initiated (Additional file 1: Supplement 1).
In order to identify relevant literature we searched the
Cochrane Library 2014, Medline 1946-August 2014 and
Embase 1974 to August 2014. Search strategies were
adapted for each database and included combinations of
medical subject headings (MeSH terms) relevant to iron
deficiency and iron deficiency anaemia in pregnancy
combined with free text search terms. Example search
strategies are provided (Additional file 2: Supplement 2).
Studies not published in English were excluded. Refer-
ence lists of relevant studies were screened to identify
further literature. The literature was reviewed against
the UKNSC criteria and the key gaps in the evidence
were identified. Criteria not relevant to iron deficiency
and iron deficiency anaemia in pregnancy were ex-
cluded, thus criteria 4, 9 and 22 were excluded as they
were specific to screening for mutations. Relevant as-
pects of the PRISMA guidelines were followed when
conducting this review.
Ethics committee approval
Ethical approval was not required for this literature review.
Results
Gaps in the evidence were identified in relation to a num-
ber of criteria as summarised in Table 2. Results for criteria
relating to policies for diagnostic investigation and treat-
ment of iron deficiency and iron deficiency anaemia were
presented together as they are discussed simultaneously in
UK clinical guidelines. Results for the criteria for adequacy
of staffing and facilitates and clinical management prior to
commencement of a screening programme were also pre-
sented together.
The condition
The condition must be an important health problem
Iron deficiency is the most common nutritional deficiency
in the world and represents the most common cause of
maternal anaemia [14]. Pregnant women and children are
particularly vulnerable to iron deficiency anaemia due to
the high demand for iron associated with growth. A num-
ber of studies were identified suggesting that there is a
high prevalence of iron deficiency anaemia in pregnancy
in the UK [2, 15].
Multiple studies of maternal anaemia have evaluated
haematological outcomes and/or measures of iron status,
however a limited number of these have evaluated clinical
consequences. Table 3 summarises a number of important
clinical outcomes of iron deficiency anaemia reported in
the literature. It also gives an indication of the quality of
the evidence based on available systematic review evi-
dence as assessed using GRADE methodology. A key in-
formation gap is the lack of clinical outcomes as reported
by women themselves.
The majority of studies analysing the impacts of iron
status tend to comprise populations with iron deficiency
anaemia. Iron deficiency per se is thought to affect tissue
oxidative capacity, whereas iron deficiency anaemia also
affects oxygen carrying capacity [16]. Whilst there are
placebo controlled trials in high income settings that
have shown that iron supplementation is effective at pre-
venting anaemia in pregnancy [3, 17]; there are no pub-
lished randomised trials that have evaluated the clinical
effects of iron deficiency without anaemia on maternal
and infant outcomes in pregnancy. Evidence from one
small cohort study in a high income country suggested a
large proportion of pregnant women with normal
haemoglobin have iron depletion, which is associated
with postnatal depression [18]. There is randomised trial
evidence of the clinical effects of iron deficiency alone
from other population groups, which may be relevant in
pregnancy e.g. iron deficiency associated with fatigue in
menstruating women [19]; with impaired physical per-
formance in female athletes and with reversible cognitive
and behavioural deficits in early infant development
[20]. Maternal iron deficiency is associated with low
neonatal iron stores in the neonate [21] and it has been
suggested that the period of particular vulnerability for
iron deficiency in the fetus and newborn is between the
last trimester and the first two years of life [22].
The epidemiology and natural history of the condition,
including development from latent to declared disease,
should be adequately understood and there should be a
detectable risk factor, disease marker, latent period or
early symptomatic stage
There are limited studies describing the epidemiology of
anaemia in pregnancy in the UK. Although haemoglobin
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Table 2 Literature review results for maternal iron deficiency and iron deficiency anaemia against UKNSC Criteria
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in normally measured in pregnancy, these data are not as
yet routinely compiled and analysed. Predictors of iron
deficiency and iron deficiency anaemia in pregnancy iden-
tified from cross-sectional studies include young maternal
age, previous pregnancy and ethnicity [2]. Health Survey
for England (HSE) data from 2004 also showed the preva-
lence of anaemia, irrespective of cause, varied between
ethnic groups. The prevalence of anaemia was highest in
Indian women at 29 %, while it was 16 % in Black Carib-
bean women and 6-7 % in Irish and Chinese women. Un-
fortunately the HSE data does not describe iron status in
these groups [23]. In some ethnic groups, the high
incidence of haemoglobinopathies, particularly alpha-
and beta- thalassaemia trait may be associated with
lower haemoglobin and contribute the high rates of
microcytic anaemia in pregnancy [24].
There is some evidence that specific dietary factors play
a role in anaemia. Vegetarians have lower iron stores but
show no differences in haemoglobin indices compared to
those who eat meat [25]. Other factors identified in the lit-
erature that place women from high-income countries in
their reproductive years at risk of iron deficiency and iron
deficiency anaemia are menstruation and intra-uterine
contraceptive devices without hormonal preparations.
These devices are thought to contribute to iron deficiency
by increasing menstrual blood loss by 30 - 50 % [26].
Other factors include weight, smoking status, blood dona-
tion intensity and previous pregnancies [27].
Early iron deficiency is characterised by diminished
iron stores. This becomes iron depletion when iron
stores are absent. Iron deficiency anaemia represents the
late stage of this spectrum. Although mild or moderate
iron deficiency and or anaemia may be asymptomatic,
there are a variety of blood iron indicators that exist to
detect early stages of disease.
All the cost-effective primary prevention interventions
should have been implemented as far as practicable
Relevant primary prevention measures include iron forti-
fication of foods and improved diet. Early studies have
evaluated the relative effectiveness and cost per DALY of
prevention strategies such as prenatal supplementation,
universal supplementation and universal fortification. It
is thought that diet based approaches and targeted sup-
plementation is particularly cost-effective and that food
fortification achieves the highest benefit-to-cost ratio [7].
There is evidence from systematic reviews that fortifica-
tion of foods with iron results in a statistically significant
improved haemoglobin and iron status in pregnancy
[28]. Iron fortification has been implemented in the UK
for a variety of foods including flour and cereals and
there is a legal minimum iron level in bread and flour
[29]. Routine prophylactic iron supplementation in preg-
nancy has not been recommended in the UK due to
concerns about side-effects, poor compliance and poten-
tial adverse effects of excess iron [4]. There is evidence
Table 3 Clinical outcomes associated with maternal iron deficiency anaemia
Maternal outcomes Infant outcomes
Evidence grade high (4) Evidence grade high (4)
Evidence grade moderate (3) Evidence grade moderate (3)
Postpartum infection Low birth weight
Preterm delivery (<37wks)
Evidence grade low (2) Evidence grade low (2)
Infection during pregnancy Mean birth weight Special care admission
Very low birth weight Birth length
Neurodevelopmental delay Head circumference at birth
Neonatal death Small for gestational age
Congenital anomaly Very premature birth (<34wks)
Evidence grade very low (1) Evidence grade very low (1)
Antepartum haemorrhage Placental malaria Still birth
Placental abruption Transfusion
Postpartum haemorrhage Premature rupture of membranes
Breast feeding duration Pre-eclampsia
Maternal wellbeing Reduced cognitive ability
Maternal death Post-partum depression
Maternal malaria Emotional instability
Side effects Lactation failure
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from a systematic review that nutrition education coun-
selling improves maternal anaemia [30], but it is unclear
how widely such counselling occurs, despite UK national
guidelines encouraging improved dietary iron intake
during pregnancy.
The test
There should be a simple, safe, precise and validated
screening test
Table 4 summarises the characteristics of available iron
indicators. In clinical practice low haemoglobin and low
mean cell volume are widely used to identify iron defi-
ciency anaemia but are not specific and may be found
in other conditions such as thalassaemia trait and
chronic disease. WHO/CDC technical guidance based
on systematic review evidence is that, in the absence of
infections, serum ferritin or serum transferrin receptor
in combination with haemoglobin provides the best ap-
proach to measuring iron status in general populations
[31]. However, serum transferrin receptor is not widely
available or used in clinical practice in many countries.
A formal study of the accuracy of diagnostic tests for
iron deficiency and a study to determine the diagnostic
accuracy of erythrocyte indices and ferritin at predict-
ing therapeutic responsiveness to oral iron therapy in
pregnancy is underway [32]. Recent advances in the
understanding of iron metabolism may define new op-
tions for screening tests. Hepcidin is a novel peptide
hormone, whose level falls in iron deficiency and so
allows the uptake of iron from the small intestine. Low
hepcidin levels may prove useful test to predict re-
sponse to absorption of oral iron in iron deficiency
[33]. An additional benefit is that, unlike ferritin, low
hepcidin levels, indicating iron deficiency, are not in-
creased by inflammation [34].
The distribution of test values in the target population
should be known and suitable cut-off level defined and
agreed
The distribution and cut-off levels for haemoglobin and
ferritin are well defined within UK guidelines. Although
anaemia in pregnancy is defined as haemoglobin <110 g/l
at any stage of pregnancy by the WHO [35], UK antenatal
guidance [4] and CDC guidance [36] define anaemia as
<110 g/l in the first trimester and <105 g/l in the second
or third trimester.
A ferritin level of 15 mcg/l defines iron deficiency and
level or 12 mcg/l iron depletion [31]. A serum ferritin level
of <15 mcg/l has a specificity of 98 % and a sensitivity of
75 % for frank iron deficiency with the ‘gold standard’ be-
ing bone marrow aspirate in women of reproductive age
[37]. The relationship between these thresholds and clin-
ical effects is uncertain. A variety of treatment levels have
been suggested in different studies [3]. The agreed treat-
ment level in UK guidelines is based on evidence that a
ferritin below 30 mcg/l indicates early iron depletion that
will worsen unless treated. However this is based on RCT
evidence in a pregnant population with a high prevalence
of endemic infection [38].
The test should be acceptable to the population
There are currently no studies that have formally evalu-
ated the acceptability of blood testing for iron deficiency
and iron deficiency anaemia in pregnancy. However,
routine blood testing for haemoglobin is already carried
out nationally as part of national antenatal guidelines.
Factors found to affect the acceptability of testing from
qualitative data from UK feasibility studies of thalassae-
mia screening in pregnancy include emotional and cog-
nitive impact, anxiety, feelings about the result and
concern for the baby’s health [39].
The treatment
There should be an agreed policy on the further diagnostic
investigation of individuals with a positive test result and
on the choices available to those individuals
There should be agreed evidence based policies covering
which individuals should be offered treatment and the
appropriated treatment to be offered
There is guidance from the UK National Institute for
Health and Care Excellence [4] and UK Royal College of
Obstetricians and Gynaecologists [6] for the management
of antenatal anaemia in relation to blood transfusion in
pregnancy. Specific UK guidance for the further diagnosis
Table 4 Characteristics of available iron status indicators adapted from [31]
Indicator Commonly available Complexity Sampling variability Validated reference material for pregnancy
Haemoglobin Y Low Low Available
Reticulocyte haemoglobin content N Low Low Available
Zinc protoporphyrin Y Low Med Not available
Mean cell volume Y Low Low Available
Transferrin receptor N Medium Medium Not available
Hepcidin N Medium/High Unknown Not available
Ferritin Y Medium Medium Available
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and management of iron deficiency in pregnancy is from
the British Committee for Standards in Haematology [5].
Within this guideline, haemoglobin and mean cell volume
are the considered as the screening test for iron deficiency
in pregnancy. Response to oral iron therapy is considered
as diagnostic of iron deficiency anaemia. This is a prag-
matic approach. Women who do not have anaemia do not
have their iron status routinely assessed. The guidelines
suggest ferritin in testing for non-anaemic women
defined at risk i.e. those with previous anaemia in preg-
nancy, multiparity (>3), consecutive pregnancy, vegetar-
ians, teenage pregnancies, recent history of bleeding
and finally those where estimation of iron stores is
necessary as significant blood loss may occur (high
bleeding risk, Jehovah’s witnesses). The guidance sug-
gests there should be systems in place for rapid review
and follow up of blood results to facilitate treatment of
those with a ferritin of <30 mcg/l.
There should be an effective treatment or intervention
for patients identified through early detection, with
evidence of early treatment leading to better outcomes
than late treatment
There are a variety of treatment options for iron defi-
ciency and iron deficiency anaemia in early pregnancy.
These include oral iron, parenteral iron (intravenous
and intramuscular preparations) as shown in Table 5. A
review of 27 systematic reviews of treatments for
maternal anaemia has summarised key gaps in the lit-
erature [40]. These included a lack of trials reporting
clinical symptoms and consequences of anaemia and
highlighted ongoing uncertainty regarding optimal dosing
and regimen for iron supplementation in pregnancy. More
recently, a systematic review and meta-analysis of 48
randomised trials and 44 cohort studies [41] has reported
that prenatal iron in the context of maternal anaemia in-
creases maternal haemoglobin reduces iron deficiency and
reduces low birth weight. These effects showed a linear
dose–response relationship at doses of 66mg/day or
higher. Only a small number of trials reported effects on
other outcomes such as stillbirth, neonatal mortality, ges-
tational diabetes and maternal infections in pregnancy,
which precluded meta-analysis. A further systematic re-
view [42] has evaluated the outcomes of intermittent iron
therapy on the neurodevelopment of children under 12.
Whilst there were demonstrable improvements in haem-
atological indices, studies were too small to demonstrate
significant associations between iron supplementation and
outcomes such as cognitive development, motor skill
development, school performance, physical capacity and
height for age. All of the trials were in developing
countries.
A Cochrane review of treatments for iron deficiency an-
aemia in pregnancy [43] included 23 trials using different
combinations of intravenous, oral and intramuscular iron.
Oral iron therapy was associated with higher rates of with-
drawal from studies due to side effects and associated poor
compliance. Intravenous iron led to greater improvements
in haematological indices, fewer problems with gastrointes-
tinal side effects and better compliance; the trials did not
assess clinical consequences. However, it should be noted
that IV iron use is only recommended in the second
trimester for safety reasons.
There is some evidence largely from cohort studies of
a U-shaped association between haemoglobin levels and
poor outcomes. Low birth weight, preterm delivery and
neonatal death were lowest at haemoglobin <90 g/L and
increased over 130 g/L [44–46].
Adequate staffing and facilities for testing, diagnosis,
treatment and programme management should be
available prior to the commencement of the screening
programme
Clinical management of the condition and patient
outcomes should be optimised in all health care providers
prior to participation in a screening programme
There is limited published evidence suggesting that man-
agement of maternal iron deficiency and iron deficiency
anaemia in the UK is not optimal. A cross-sectional, mul-
ticentre study found that of women found to be
Table 5 Iron treatments available suitable for use in pregnancy
Iron preparation Year first authorised (UK) Single/Multiple infusion doses Safety in pregnancy Cost
Oral Ferrous sulphate - - 1st 2nd 3rd trim £0.97/28 tablets*1
Oral Ferrous fumarate - - 1st 2nd 3rd trim £0.79/28 tablets*1
Oral Ferrous gluconate - - 1st 2nd 3rd trim £1.95/20 tablets*1
IV iron sucrose (Venofer ®) 1998 Multiple 2nd 3rd trim £148.48*2
IV iron dextran (Cosmofer®) 2001 Single 2nd 3rd trim £115.57*2
IV iron ferric carboxymaltose (Ferinject®) 2007 Single 2nd 3rd trim £286.5*2
IV Ferric iron isomastoside (Monofer®) 2010 Single 2nd 3rd trim £254.25*12
This table does not include over the counter multinutrient supplements that contain iron
*1cost of tablets as per British National Formulary 2014 [53]
*2cost of cumulative dose as per British National Formulary 2014 [53]. Dose calculated based on assumed patient Hb, patient weight of 65kg and target Hb of 150
g/l and target iron depot store targets as per electronic medicines compendium [54]. Cost does not include diluent or nursing time
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anaemic during antenatal visits, only 32 % had their fer-
ritin level checked. Where the ferritin level was found
to be <30 mcg/l, only half of women had iron pre-
scribed (Barroso, et al. 2011). There was wide variation
in the implementation of existing guidance between the
centres. Although barriers to anaemia control strategies
have been described in the literature for low and mid-
dle income countries [47], these are not well described
for high income countries.
The screening programme
There should be evidence from high quality randomised
controlled trials that the screening programme is
effective in reducing mortality or morbidity
There have been no screening programmes or rando-
mised trials of screening programmes for iron deficiency
or iron deficiency anaemia in pregnancy in the published
literature. There are some studies that have evaluated
screening for iron deficiency anaemia in infants [48, 49]
and male and female adolescents in the USA [50] with
little evidence of benefit.
There should be evidence that the complete screening
programme (test, diagnostic procedures, treatment or
intervention is clinically, socially and ethically acceptable
to health professionals and the public
There have been no trials that have evaluated the
clinical, social or ethical acceptability of a screening
programme to treat iron deficiency and iron deficiency
anaemia in pregnancy. Factors identified in the litera-
ture that would affect the clinically acceptability have
been discussed with respect to evidence for clinical out-
comes in section 2 and 7. There is reason to believe that
an effective programme would be considered socially and
ethically acceptable from experience with the thalassae-
mia and sickle screening antenatal programmes in the
UK [39].
The benefit from the screening programme should
outweigh the physical and psychological harm (caused by
the test, diagnostic procedures and treatment)
The anticipated benefits of such a programme would
include the early identification of latent iron defi-
ciency or iron deficiency anaemia, and would lead to
improved maternal and infant outcomes. Potential
causes of harm related to screening include false posi-
tive results and associated anxiety. False positive diag-
noses of anaemia and or iron deficiency may lead to
inappropriate iron supplementation. Although it might
be anticipated that the benefits would outweigh the
risks, we did not identify any formal evaluations of
screening programmes for maternal iron deficiency
and/or anaemia.
The opportunity cost of the screening programme
(including testing, diagnosis and treatment,
administration, training and quality assurance) should
be economically balanced in relation to expenditure on
medical care as a whole (i.e. Value for money).
Assessment against these criteria should have regard to
evidence from cost benefit and/or cost effectiveness
analyses and have regard to the effective use of
available resource
There have been no economic studies evaluating the
effectiveness of systematic population screening or
whole programmes for treating iron deficiency or iron
deficiency anaemia in pregnancy. It is difficult to
evaluate the economic implications in the absence of
unequivocal evidence of benefit on clinical outcomes
in pregnancy.
All other options for managing the condition should
have been considered (e.g. improving treatment,
providing other services), to ensure that no more cost-
effective intervention could be introduced or current
interventions increased within the resources available
Primary prevention of iron deficiency and iron defi-
ciency anaemia in the UK has been described in sec-
tion 3. Routine supplementation with oral iron tablets
in the UK not recommended as it is in other countries
such as the US. There are no further interventions
known to be more cost effective that could be intro-
duced in the UK.
There should be a plan for managing and monitoring the
screening programme and an agreed set of quality
assurance standards. Adequate staffing and facilities for
testing, diagnosis, treatment and programme
management should be available prior to the
commencement of the screening programme
Whilst there have been no randomised trials of a
screening programme, other similar antenatal screening
programmes e.g. sickle cell and thalassaemia, have
comprehensive plans for monitoring and agreed quality
assurance standards [51]. There have been no formal
studies to establish adequate staffing testing, diagnosis
and treatment for a programme that would address iron
deficiency and iron deficiency anaemia.
Evidence-based information, explaining the consequences
of testing, investigation and treatment, should be made
available to potential participants to assist them in
making an informed choice
There is no evidence-based information specific to a
screening programme for iron deficiency or iron defi-
ciency anaemia in pregnancy. The infrastructure for de-
livering information to participants to assist them in
making an informed choice exists within antenatal and
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postnatal care in the UK National Health Service (NHS).
The characteristics of what makes information accessible
and acceptable to pregnant women in allowing them to
make an informed choice has been studied in the con-
text of antenatal screening programmes for other condi-
tions such as thalassaemia [39].
Public pressure for widening the eligibility criteria, for
reducing the screening interval and for increasing the
sensitivity of the testing process, should be anticipated.
Decisions about these parameters should be scientifically
justifiable to the public
The sensitivity of the testing process may be increased as
ferritin testing in pregnancy becomes more widespread in
practice. The sensitivity of the testing process may also be
improved, if and when, newer iron status indicators such
as hepcidin become more affordable and widely available.
Given the side effects of oral iron, it is possible that the
eligibility criteria for those requiring IV iron may widen.
Discussion
This review has identified a number of significant gaps
in the evidence base required to evaluate the case for a
structured or coherent national screening programme
for iron deficiency or iron deficiency anaemia in mater-
nity in the UK. This is a common problem: despite na-
tional guidelines, studies continue to document a high
burden of anaemia in pregnancy; and a recent multicen-
tre study in UK documented an overall prevalence of
maternal anaemia at 24 % during the antenatal period
[2]. There is evidence that poor outcomes such as low
birth weight and post-partum infection are associated
with iron deficiency anaemia. However, evidence for the
association of iron deficiency anaemia or iron deficiency
with other important clinical outcomes, including mater-
nal well-being, are lacking or inconsistent, While there
is good evidence of improvements in haematological in-
dices with iron supplementation, it is not clear what size
of effect early detection and iron supplementation would
have on improved clinical outcomes. Oral and intraven-
ous iron are associated with side effects but the optimal
strategy for effective dosing and administration, to
maximize compliance, are not known. The natural his-
tory and effects of iron depletion (without anaemia)
have not been defined and there have been no robust
evaluations of the cost-effectiveness of screening pro-
grammes for iron deficiency anaemia.
Strengths and limitations
The main strength of this study is that it provides a com-
prehensive analysis of the gaps in the scientific literature
with particular reference to the UK against the UKNSC
screening criteria and so highlights key policy and re-
search areas that need to be addressed to reduce the
prevalence of iron deficiency and iron deficiency anaemia
in pregnancy. A full systematic review on all elements of
the National Screening Committee criteria was beyond
the scope of this article; we carried out a structured review
to highlight the key evidence addressing each criterion.
An additional limitation was the exclusion of papers that
were not published in the English language.
Research recommendations
Priorities for research should be directed towards the
evidence gaps highlighted in Table 2. These include:
changes in the biology of systemic iron homeostasis dur-
ing pregnancy and the natural history of iron depletion,
prognostic evaluations of different diagnostic markers of
iron status such as ferritin, soluble transferrin receptor,
zinc protoporphyrin and hepcidin which change during
pregnancy, the clinical consequences of iron depletion
or anaemia for the mother and infant. However, a crucial
gap exists between recommendations from clinical
guidelines and clinical practice indicating the need for
further research to understand the barriers to implemen-
tation of practice guidelines in maternity. A better un-
derstanding of the issues women feel relevant to their
care is important and likely to have implications for
compliance with therapy. Future studies should include
patient reported outcome measures and functional or
quality of life measures relevant to anaemia during preg-
nancy and the post-partum period.
The major gaps in the evidence for a screening
programme for iron deficiency and iron deficiency anaemia
are of data from high quality randomised controlled trials
that the screening programme is effective in reducing mor-
tality or morbidity, that the benefit from the screening
programme should outweigh the physical and psychological
harm (caused by the test, diagnostic procedures and treat-
ment) and that the opportunity cost of the screening
programme should be economically balanced in relation to
expenditure on medical care as a whole (i.e. Value for
money).
It is clear, that randomised trials comparing different
policies for anaemia recognition and treatment are re-
quired; including evaluation of a more robust screening
programme against conventional best practice which
would provide high quality evidence as to whether better
clinical outcomes would be achieved with screening. An
alternative approach would be to consider whether
targeted screening would be beneficial in women consid-
ered to be at high risk of iron deficiency in pregnancy.
An initial pilot study could be designed to assess
whether screening with iron replacement would lead to
improved clinical outcomes. These studies should be
coupled with economic analyses to evaluate the oppor-
tunity costs and whether the clinical benefits would off-
set the costs of implementing and monitoring such a
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programme. Within the UK, there is the opportunity to
design studies that evaluate some of these questions in
relation to the existing national antenatal haemoglobin-
opathy screening programme.
Conclusion
Iron deficiency and iron deficiency anaemia are common
in pregnancy yet the clinical consequences; particularly
for mild and moderate anaemia, remain poorly under-
stood. Concerted efforts are required to evaluate the
case for screening for iron deficiency and iron deficiency
anaemia in pregnancy.
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